Abstract:The main focus for the development of adenosine targets as analgesics to date has been A1Rs due to its antinociceptive profile in various preclinical pain models. The usefulness of systemic A1R agonists may be limited by other effects (cardiovascular, motor), but enhanced selectivity for pain might occur with partial agonists, potent and highly selective agonists, or allosteric modulators. A2AR agonists exhibit some peripheral pronociceptive effects, but also act on immune cells to suppress inflammation and on spinal glia to suppress pain signaling and may be useful for inflammatory and neuropathic pain. A2BR agonists exhibit peripheral proinflammatory effects on immune cells, but also spinal antinociceptive effects similar to A2AR agonists. A3Rs are now demonstrated to produce antinociception in several preclinical neuropathic pain models, with mechanistic actions on glial cells, and may be useful for neuropathic pain. Endogenous adenosine levels can be augmented by inhibition of metabolism (via adenosine kinase) or increased generation (via nucleotidases), and these approaches have implications for pain. Endogenous adenosine contributes to antinociception by several pharmacological agents, herbal remedies, acupuncture, transcutaneous electrical nerve stimulation, exercise, joint mobilization, and water immersion via spinal and/or peripheral effects, such that this system appears to constitute a major pain regulatory system. Finally, caffeine inhibits A1-, A2A- and A3Rs with similar potency, and dietary caffeine intake will need attention in trials of: (a) agonists and/or modulators acting at these receptors, (b) some pharmacological and herbal analgesics, and (c) manipulations that enhance endogenous adenosine levels, all of which are inhibited by caffeine and/or A1R antagonists in preclinical studies. All adenosine receptors have effects on spinal glial cells in regulating nociception, and gender differences in the involvement of such cells in chronic neuropathic pain indicate gender may also need attention in preclinical and human trials evaluating the efficacy of adenosine-based analgesics.

Optical Control of Adenosine-Mediated Pain Modulation

Photosensitive and Photoswitchable TRPA1 Agonists Optically Control Pain Through Channel Desensitization

An opioid efficacy switch for reversible optical control of peripheral analgesia

Optical Control of Adenosine A 2A Receptor Using Istradefylline Photosensitivity

Targeting Adenosine Receptors: A Potential Pharmacological Avenue for Acute and Chronic Pain

Uncovering the Mechanisms of Adenosine Receptor-Mediated Pain Control: Focus on the A3 Receptor Subtype

Positive allosteric mechanisms of adenosine A1 receptor-mediated analgesia

A “double-edged” role for type-5 metabotropic glutamate receptors in pain disclosed by light-sensitive drugs

Photoswitchable Diazocine Derivative for Adenosine A 3 Receptor Activation in Psoriasis

A 'double-edged' role for type-5 metabotropic glutamate receptors in pain disclosed by light-sensitive drugs

Optogenetic and Chemogenic Control of Pain Signaling: Molecular Markers

In silico identification of A1 agonists and A2a inhibitors in pain based on molecular docking strategies and dynamics simulations

Bridging the translational gap: adenosine as a modulator of neuropathic pain in preclinical models and humans

Adenosine receptor targets for pain

Sustained Elevated Adenosine Via ADORA2B Promotes Chronic Pain Through Neuro-immune Interaction.

Design, synthesis and pharmacological characterization of the first photoswitchable small-molecule agonist for the Atypical Chemokine Receptor 3

The role of adenosine receptor ligands on inflammatory pain: possible modulation of TRPV1 receptor function

A general method for near-infrared photoswitching in biology, demonstrated by the >700 nm photocontrol of GPCR activity in brain slices

Photoswitchable carbamazepine analogs for non‐invasive neuroinhibition in vivo

Kinetic Basis for the Design of Azobenzene-Based Photoswitchable A 2a Adenosine Receptor Ligands

Cell‐Specific Optical Control of AMPA Glutamate Receptors with a Photoswitchable Tethered Antagonist